Biopharmaceutical News and Research

RSS

PAREXEL International expands clinical trial site alliance network

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the continued expansion of its clinical trial site alliance network, an extensive network of investigator sites and Site Management Organizations (SMOs) that enables PAREXEL to quickly access and enroll patient populations for clients' clinical trials worldwide.

From Parexel 18 Feb 2015

Biotech investor invests in InterCure to increase stake in XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that Israeli biotech investor Alex Rabinovich, its largest shareholder, increased his stake in the Company through his investment in InterCure, an XTL subsidiary, and recent purchases of XTL stock in the market.

17 Feb 2015

Imperial College London to invest in new facility at Babraham Campus to support dynamic bioscience companies

Imperial College London is to invest in a new facility at the Babraham Research Campus in Cambridge to support spin-out and scale-up companies, and maximise the impact of research from universities.

From Abzena 13 Feb 2015

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severity in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.

13 Feb 2015

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV").

9 Feb 2015

MedImmune, University of Manchester sign new research collaboration

MedImmune, the global biologics research and development arm of AstraZeneca, and The University of Manchester have entered into a new research collaboration to generate cutting-edge protein formulation science.

5 Feb 2015

Immuron begins patient recruitment for Phase 2 clinical trial of IMM-124E NASH drug candidate

Australian biopharmaceutical company Immuron Limited has today announced a significant milestone in its Phase 2 clinical trial for non-alcoholic steatohepatitis (NASH) with the recruitment of its first two patients at Duke University in the United States. It is expected that further recruitment at Duke and other sites in the US and Australia will follow in early course.

3 Feb 2015

Altered dopamine signaling may contribute to autism

Newly discovered genetic variations linked to autism spectrum disorder (ASD) disrupt the function of the dopamine transporter, suggesting that altered dopamine signaling contributes to this common developmental condition, according to a Vanderbilt University-led research team.

31 Jan 2015

Project Spark to advance neuroprotective drug for schizophrenia-associated cognitive impairment

A public-private consortium led by the biotech Iproteos -based at Parc Científic de Barcelona (PCB)-, and comprised by the biopharmaceutical company Ascil-Biopharma, the Institute for Biomedical Research (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU) has launched a project to advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders.

31 Jan 2015

SynTheAll Pharmaceutical wins 2015 CMO Leadership Award

WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, announced today that SynTheAll Pharmaceutical Co., Ltd., WuXi's small-molecule manufacturing subsidiary, has won a 2015 CMO Leadership Award, which is presented by Life Science Leader magazine based on research conducted by Nice Insight.

30 Jan 2015

Researchers move one step closer to treating diabetes with human probiotic pill

Science may be one step closer to treating diabetes with a human probiotic pill, according to new Cornell University research.

30 Jan 2015

Innovent Biologics raises $100 million in Series C financing

Innovent Biologics, Inc., a privately held Chinese biopharmaceutical company dedicated to the development and manufacturing of complex, high-end biologics to be marketed in the rapidly growing Chinese market and elsewhere worldwide that meet EMEA and FDA/cGMP standards, has raised $100 million in Series C financing.

22 Jan 2015

TPI obtains GMP certification for Qionglai Tianyin Facility

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced that the TPI's Qionglai Tianyin Facility (QLF) has received its Good Manufacturing Practice (GMP) certificate from the China Food & Drug Administration's (CFDA) with the GMP certification processing number: SC20140067.

20 Jan 2015

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%.

20 Jan 2015

Celator Pharmaceuticals' CPX-351 receives FDA Fast Track designation for secondary AML treatment

Celator Pharmaceuticals, Inc., a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the U.S. Food and Drug Administration granted Fast Track designation for CPX-351 (cytarabine:daunorubicin) for the treatment of elderly patients with secondary Acute Myeloid Leukemia (AML).

20 Jan 2015

FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the United States Food and Drug Administration has removed the partial clinical hold on the Company's aldoxorubicin clinical trials.

20 Jan 2015

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea.

14 Jan 2015

MGB Biopharma provides update on business performance for 2014

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, provides an update on its business performance for 2014. MGB Biopharma is developing a pipeline of novel antimicrobials that puts it at the forefront of addressing the major global problem of antimicrobial resistance.

12 Jan 2015

Crown Bioscience to double capacity of PRECOS facility, rename UK site

Crown Bioscience, Inc., a leading global drug discovery and development service company, has announced that it will double the capacity of the recently acquired PRECOS (Preclinical Oncology Services Limited) facility and will rename the site Crown Bioscience UK Ltd.

9 Jan 2015

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients.

8 Jan 2015

Biopharmaceutical News and Research

PAREXEL International expands clinical trial site alliance network

Biotech investor invests in InterCure to increase stake in XTL Biopharmaceuticals

Imperial College London to invest in new facility at Babraham Campus to support dynamic bioscience companies

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

MedImmune, University of Manchester sign new research collaboration

Immuron begins patient recruitment for Phase 2 clinical trial of IMM-124E NASH drug candidate

Altered dopamine signaling may contribute to autism

Project Spark to advance neuroprotective drug for schizophrenia-associated cognitive impairment

SynTheAll Pharmaceutical wins 2015 CMO Leadership Award

Researchers move one step closer to treating diabetes with human probiotic pill

Innovent Biologics raises $100 million in Series C financing

TPI obtains GMP certification for Qionglai Tianyin Facility

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Celator Pharmaceuticals' CPX-351 receives FDA Fast Track designation for secondary AML treatment

FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

MGB Biopharma provides update on business performance for 2014

Crown Bioscience to double capacity of PRECOS facility, rename UK site

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

Event guide: World ADC San Diego eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News